Oncotype DX® breast cancer assay to quantify the risk of disease recurrence and predict adjuvant hemotherapy benefit
Medical Services Advisory Committee
Record ID 32015000439
English
Authors' recommendations:
After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict the need for adjuvant chemotherapy, MSAC did not support public funding because of limitations identified in the performance, clinical utility, cost-utility, and utilisation of the test.
In conveying this advice, MSAC recognised the desire for patients and clinicians to have greater clarity in predicting risk of recurrence and response to therapy options before making decisions regarding chemotherapy. Nonetheless, given the limitations identified above, MSAC was not prepared to support public funding. MSAC considered that any further reapplication should be made via ESC and would require
external evaluation.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1342.1-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Neoadjuvant Therapy
- Antineoplastic Combined Chemotherapy Protocols
- Female
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.